Hepatitis C News

AMSTERDAM — Six weeks of triple combination therapy induced sustained virologic response in a cohort of patients with genotype 1 HCV but not genotype 3, according to data presented at the International Liver Congress.

AMSTERDAM — In this exclusive video from International Liver Congress, Andrew Talal, MD, MPH, from the University of Buffalo, New York, discusses results of a study that used fine-needle aspiration to determine HCV RNA decline in plasma in patients treated with a direct-acting antiviral regimen.

AMSTERDAM — A fixed, half-dose combination of Harvoni was associated with sustained virologic response rates of 99% or greater in a cohort of children aged 6 to 11 years, according to data presented at the International Liver Congress.

AMSTERDAM — A presenter at today’s viral hepatitis session at the International Liver Congress called on the clinical community to push the envelope in using generic direct-acting antiviral therapies.

AMSTERDAM — Approximately one-third of children under 18 years in the United Kingdom with hepatitis C developed serious long-term liver disease, according to data presented at the International Liver Congress.

AMSTERDAM — Zepatier was associated with SVR12 rates above 95% in a real-world, Veterans Affairs cohort, according to data presented at the International Liver Congress.

AMSTERDAM — Norfloxacin yielded improved 6-month survival compared with placebo in a cohort of HCV patients with Child-Pugh C cirrhosis, according to data presented at the International Liver Congress.

AMSTERDAM — Curing patients with cirrhosis of hepatitis C virus could alter the inflammatory milieu and have an impact on the way CD8+ T-cells surveil potential carcinoma, according to data presented at the International Liver Congress.

AMSTERDAM — While progress has been made in the global burden of hepatitis, there is still much to be done to achieve eradication by 2030, according to WHO, which released its first ever global hepatitis report at the International Liver Congress.

AMSTERDAM — Eight weeks of the fixed-dose combination of glecaprevir/pibrentasvir produced a 95% sustained virologic response rate in patients with genotype 3 hepatitis C virus, according to data presented at the International Liver Congress.